Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study
- 1 October 2009
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 20 (9), 794-799
- https://doi.org/10.1097/cad.0b013e32832f4abe
Abstract
This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors. Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4–22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1). Eighteen patients received concomitant systemic radiochemotherapy. A total of 88 intrathecal injections of liposomal cytarabine (dose range, 20–50 mg) were administered with concomitant dexamethasone prophylaxis. The median number of doses per patient was four (range, 1–10). Duration of treatment ranged from ½ to 10 months. Eleven patients (57.9%) did not show any side effects, whereas eight patients (42.1%) developed side effects related to either chemical arachnoiditis (n = 4) or neurological progression (n = 2). Less typical treatment-related symptoms (e.g. lethargy, ataxia, and slurred speech) were observed in two patients. Treatment with intrathecal liposomal cytarabine was discontinued twice because of side effects. In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors. Proof of efficacy requires a prospective single-agent phase II study.Keywords
This publication has 31 references indexed in Scilit:
- Metastatic ependymoma: A multi‐institutional retrospective analysis of prognostic factorsPediatric Blood & Cancer, 2007
- Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomasBritish Journal of Cancer, 2006
- Salvage high-dose chemotherapy for children with extragonadal germ-cell tumoursBritish Journal of Cancer, 2005
- Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH)Journal of Neuro-Oncology, 2005
- Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapyEuropean Journal Of Cancer, 2005
- Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the german prospective randomized trial hit ’91International Journal of Radiation Oncology*Biology*Physics, 2000
- Verbesserte Prognose intracranialer Keimzelltumoren durch intensivierteTherapie: Ergebnisse des Therapieprotokolls MAKEI 89Klinische Padiatrie, 1993
- Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failureInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Improvements in the radiotherapy of medulloblastoma, 1946–1975Cancer, 1980
- Improved survival of patients with intracranial ependymomas by irradiation: Dose selection and field extensionCancer, 1975